Skip to main content
Premium Trial:

Request an Annual Quote

Danaher Completes Beckman Coulter Acquisition

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Danaher has completed its acquisition of Beckman Coulter following the expiration last night of a subsequent offering period in the tender offer.

As reported by GenomeWeb Daily News earlier this week, Danaher had completed the tender offer last Friday, with about 88.08 percent of all outstanding shares having been tendered. Following the subsequent offering period, a total of 66,168,634 shares of Beckman common stock representing around 92.38 percent of the outstanding shares had been validly tendered and not withdrawn.

Beckman stockholders who did not tender their shares will receive the offer price of $83.50 per share.

The firms inked the $6.8 billion deal in February. Beckman will become part of Danaher's Life Sciences and Diagnostics segment, joining the AB Sciex, Leica, Radiometer, and Molecular Devices businesses. It provides Danaher with one of the world's largest diagnostics players. Beckman reported full-year 2010 clinical diagnostics sales of $3.21 billion, up 15 percent year over year.

The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.